CLINICAL IMPACT OF 18F FDG PET-CT ON MANAGEMENT OF GERM CELL TUMORS

  • Saima Riaz Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore
  • Humayun Bashir Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore
  • Nargis Muzzafar Sultan Qaboops Uni Hospital
  • Ahmed Murtaza King Saud University Hospital, Riyadh
  • Amin Hayee Pathology Department, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore

Abstract

Purpose: The purpose of this study was to review the impact of 18F- fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) scans on the management of patients with germ cell tumours (GCT) at our centre.

Methods: A descriptive, cross-sectional, retrospective review of a total of 29 FDG PET-CT scans acquired in 20 patients with GCT between December 2009 and May 2013.

Results: Sixteen males and four females with the average age of 34.4 years (+18SD) were identi ed who underwent FDG PET-CT scans for treatment response/outcome evaluation on an average period of 3 months after completion of therapy. Hypermetabolic residual disease (PET-CT positive) was identi ed in 8 (40%). 6 (30%) had non-FDG-avid residual morphologic disease (PET negative and CT positive) and 6 (30%) were disease free (PET-CT negative). FDG PET-CT led to change in the management plan of 12 (60%) of cases as compared to the CT alone ndings. Follow-up was available for a median of 2.9 years (±1.5 SD). The overall 5-year disease-free survival was found to be PET-CT positive patients = 62%, PET-negative and CT-positive patients = 80% and PET-CT-negative patients = 100%.

Conclusion: FDG PET-CT scanning has a potential role in the evaluation of response to treatment and can predict the survival outcome.

Key words: 18F- uorodeoxyglucose positron emission tomography computed tomography, disease-free survival, germ cell tumour, standardised uptake value 

References

Chief P. Recent advances in molecular and cell biology of testicular germ-cell tumours. Int Rev Cell Mol Biol 2014;312: 79 100.

Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of uorine-18- uorodeoxyglucose positron emission tomography in the post chemotherapy management of patients with seminoma: Systematic review and meta- analysis. Biomed Res Int 2014;2014:852681.

Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998;39:815-22.

Oldenburg J, Fossa SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24: 25-32.

Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumours. Urol Int 2002;68:157-63.

Gerl A, Clemm C, Schmeller N, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994;70:960-5.

De Santis M, Maj-Hes A, Bachner M. Positron Emission Tomography (PET) in Germ Cell Tumours (GCT). Imaging in Oncological Urology. London: Springer; 2009. p. 305-13.

Bhatti AB, Ahmed I, Ghauri RK, et al. Clinical profile, treatment and survival outcome of testicular tumors:APakistani perspective.Asian Pac J Cancer Prev 2014;15:277-80.

Bachner M, LoriotY, Gross-Goupil M, etal.2-18 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for post chemotherapy seminoma residual lesions: A retrospective validation of the SEMPET trial. Ann Oncol 2012;23: 59-64.

Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post- chemotherapy seminoma residuals. Eur J Radiol 2005;54: 284-8.

De Santis M, Becherer A, Bokemeyer C, et al. 2-18 uoro- deoxy-D-glucose POSITRON emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial J Clin Oncol 2004;22:1034-9.

Sharma P, Jain TK, Parida GK, et al. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours. Br J Radiol 2014; 87:20140263.

Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: Testicular cancer. J Natl Compr Canc Netw 2009;7:672-93.

Buchler T, Dusek P, Brisuda A, et al. A positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors. Klin Onkil 2012;25:178-83.

Buchler T, Simonova K, Fencl P, et al. Clinical outcomes of patients with nonseminimatous germ cell tumours and negative post chemotherapy positrom emission tomography. Cancer Invest 2012;25:487-92.

Published
2015-11-01
How to Cite
1.
Riaz S, Bashir H, Muzzafar N, Murtaza A, Hayee A. CLINICAL IMPACT OF 18F FDG PET-CT ON MANAGEMENT OF GERM CELL TUMORS. J Cancer Allied Spec [Internet]. 2015Nov.1 [cited 2020Dec.4];1(2). Available from: https://journals.sfu.ca/jcas/index.php/jcas/article/view/34
Section
Original Research Article